Moody National Bank Trust Division maintained its stake in Merck & Company, Inc. (NYSE:MRK) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 32,957 shares of the company’s stock at the close of the second quarter. Moody National Bank Trust Division’s holdings in Merck & were worth $2,112,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the stock. Vigilant Capital Management LLC increased its stake in Merck & by 16.7% during the first quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock worth $111,000 after acquiring an additional 250 shares during the last quarter. Cascade Investment Advisors Inc. increased its stake in Merck & by 15.5% during the second quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock worth $111,000 after acquiring an additional 232 shares during the last quarter. Harbour Capital Advisors LLC acquired a new stake in Merck & during the first quarter worth $127,000. Mascoma Wealth Management LLC increased its stake in Merck & by 8.2% during the second quarter. Mascoma Wealth Management LLC now owns 2,474 shares of the company’s stock worth $159,000 after acquiring an additional 187 shares during the last quarter. Finally, Gradient Investments LLC increased its stake in Merck & by 17.5% during the second quarter. Gradient Investments LLC now owns 2,710 shares of the company’s stock worth $174,000 after acquiring an additional 404 shares during the last quarter. Hedge funds and other institutional investors own 72.91% of the company’s stock.

MRK has been the subject of several recent analyst reports. Cowen and Company reissued a “hold” rating and set a $70.00 target price on shares of Merck & in a research note on Friday, September 1st. Zacks Investment Research cut Merck & from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Credit Suisse Group reissued a “buy” rating on shares of Merck & in a research note on Tuesday, June 13th. Jefferies Group LLC reissued a “sell” rating and set a $52.00 target price on shares of Merck & in a research note on Sunday, August 20th. Finally, Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $74.00 target price (up previously from $70.00) on shares of Merck & in a research note on Thursday, July 27th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $69.81.

Merck & Company, Inc. (NYSE MRK) opened at 64.55 on Monday. The firm has a market capitalization of $176.05 billion, a PE ratio of 34.95 and a beta of 0.80. Merck & Company, Inc. has a 1-year low of $58.29 and a 1-year high of $66.80. The company’s 50-day moving average price is $64.27 and its 200 day moving average price is $63.68.

Merck & (NYSE:MRK) last posted its quarterly earnings data on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.87 by $0.14. The company had revenue of $9.93 billion for the quarter, compared to analysts’ expectations of $9.75 billion. Merck & had a net margin of 17.14% and a return on equity of 26.02%. Merck &’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.93 earnings per share. On average, equities analysts anticipate that Merck & Company, Inc. will post $3.87 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 6th. Investors of record on Friday, September 15th were given a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 2.91%. The ex-dividend date was Thursday, September 14th. Merck &’s dividend payout ratio (DPR) is 76.11%.

TRADEMARK VIOLATION NOTICE: “Moody National Bank Trust Division Continues to Hold Holdings in Merck & Company, Inc. (MRK)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/09/moody-national-bank-trust-division-continues-to-hold-holdings-in-merck-company-inc-mrk.html.

Merck & Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Stock Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related stocks with our FREE daily email newsletter.